2 results
Approved WMORecruiting
The primary aim of the trial is to demonstrate the non-inferiority of AMT-061 (2 × 1013 gc/kg) during the 52 weeks following establishment of stable factor IX expression (months 6 to 18) post-treatment (AMT-061) follow-up compared to standard of…
Approved WMORecruiting
This trial aims to investigate whether peroperative administration of TXA reduces haemorrhage rates in patients who undergo metabolic surgery.